

Expert Debate: Combination Versus Monotherapy Strategies in Favourable Risk mRCC

Symposium at the International Urology Cancer Summit 2025, Portsmouth, UK
September 5, 2025, 10.30-10.50 AM

Learning objectives

By participating in this symposium, learners will be better able to:

- Articulate the clinical evidence and guidelines for use of frontline IO-based combination therapies and single-agent TKIs in favourable risk mRCC
- Develop personalised treatment strategies for patients with favourable risk mRCC, guided by clinical characteristics and patient preferences

Faculty

- *Chair:* Laurence Albiges, Head of Department of Oncology, Institut Gustave Roussy, Villejuif, France
- Ricky Frazer, Consultant Medical Oncologist, Velindre Cancer Centre, Cardiff, UK
- Will Ince, Clinical Associate Professor and Consultant Clinical Oncologist, Addenbrooke's Hospital, Cambridge, UK

Agenda

Duration (minutes)	Topic	Speaker(s)
5	Welcome and introduction	Laurence Albiges
5	Frontline treatment in favourable risk mRCC: the role of IO-based combination therapies	Will Ince
5	Frontline treatment in favourable risk mRCC: the role of single-agent TKIs	Ricky Frazer
5	Panel discussion and key takeaways	Laurence Albiges & Panel Discussion